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Abstract: Pulmonary arterial hypertension (PAH) is a rare fatal disease. Current disease-speciﬁc 
therapeutic interventions in PAH target 1 of 3 established pathways in disease pathobiology: 
prostacyclin, nitric oxide, and endothelin-1. Endothelin receptor antagonists (ERAs) act on the 
endothelin pathway by blocking binding of endothelin-1 to its receptors (endothelin type-A 
[ETA] and/or type-B [ETB]) on the surface of endothelial and smooth muscle cells. Ambrisentan 
is an oral, once-daily, ETA-selective ERA in development for the treatment of PAH. In Phase 
3 clinical trials in patients with PAH, ambrisentan (2.5–10 mg orally once-daily) improved 
exercise capacity, Borg dyspnea index, time to clinical worsening, WHO functional class, 
and quality of life compared with placebo. Ambrisentan provided durable (at least 2 years) 
improvement in exercise capacity in a Phase 2 long-term extension study. Ambrisentan was 
well tolerated with a lower incidence and severity of liver function test abnormalities compared 
with the ETA/ETB ERA, bosentan, and the ETA-selective ERA, sitaxsentan. Ambrisentan does 
not induce or inhibit P450 enzymes; therefore, ambrisentan is unlikely to affect the pharmaco-
kinetics of P450-metabolized drugs. The demonstration of clinical efﬁcacy, low incidence of 
acute hepatic toxicity, and low risk of drug–drug interactions support the role of ambrisentan 
for the treatment of PAH. 
Keywords: endothelin receptor antagonist, pulmonary arterial hypertension, endothelin-1, time 
to clinical worsening, Borg dyspnea index
Pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a chronic, progressive disease character-
ized by increased pulmonary vascular resistance of the lung microvasculature, intimal 
hyperplasia and smooth muscle cell hypertrophy, and in situ thrombosis (Rubin 2006). 
PAH disease progression leads to right heart failure and death (Vlahakes et al 1981; 
D’Alonzo et al 1991; Rich 2001). 
PAH is deﬁned by mean pulmonary arterial pressure that exceeds 25 mm Hg at 
rest or 30 mm Hg during exercise, with mean pulmonary-capillary wedge pressure or 
left ventricular end diastolic pressure ≤15 mm Hg and pulmonary vascular resistance 
greater than 3 Wood units (Hatano et al 1975; Barst et al 2004b). Unfortunately and 
despite signiﬁcant efforts to diagnose patients earlier in the disease process, the disease 
is most often diagnosed months or years after symptoms ﬁrst appear. As a consequence, 
the majority of patients present with advanced disease and marked functional impair-
ment (Hoeper 2005). 
Clinical classiﬁcation
According to the Venice 2003 World Health Organization (WHO) symposium on PAH 
classiﬁcation, the broader category of pulmonary hypertension (PH) is subdivided into 
5 categories based on association with heart disease, lung disease, thromboembolic Vascular Health and Risk Management 2007:3(1)  12
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disease or miscellaneous conditions (Table 1) (Simonneau 
et al 2004). PAH can occur in the absence of an associated 
disorder as either idiopathic PAH (IPAH) or familial PAH 
(FPAH) (Rubin et al 2005a). Additionally, PAH can occur 
as a complication of systemic conditions, such as connective 
tissue disease, congenital heart disease, portal hypertension, 
HIV infection, or from the use of anorexigens, amphetamines, 
or cocaine (Rubin et al 2005a). 
One to 2 persons per million per year are diagnosed with 
either IPAH or FPAH (Abenhaim et al 1996), with at least 
6% of these patients having FPAH (Rich et al 1987). However, 
IPAH comprises the minority of PAH cases, and the inci-
dence of PAH associated with other conditions is generally 
higher than that for IPAH/FPAH. Histologic features consis-
tent with PAH and clinically evident pulmonary hypertension 
have been observed in connective tissue diseases including 
scleroderma, systemic lupus erythematosus, mixed connec-
tive-tissue disease, polymyositis, dermatomyositis, and rheu-
matoid arthritis (Rich 2001; Farber et al 2004). Estimates for 
PAH in scleroderma patients vary widely from 11% to 35%, 
representing an incidence of 50 to 230 cases per million (Rich 
2001). In patients infected with HIV, the incidence of HIV 
associated PAH is estimated at 0.1% (Humbert et al 2001). 
Unlike PAH associated with noninfectious diseases, PAH 
associated with HIV demonstrates a geographic distribution 
with sub-Saharan Africa, South Asia, and Southeast Asia 
representing >80% of total HIV-associated PAH (UNAIDS 
2006). The incidence of PAH associated with anorexigens 
is cyclical in nature and varies depending on the availability 
of speciﬁc appetite suppressants. An association was ﬁrst 
identiﬁed in the 1960s when an epidemic of PAH occurred 
in Switzerland, Austria, and Germany in persons taking the 
anorexigen aminorex fumarate (Rich et al 2000). Use of 
anorexigens including fenﬂuramine and dexfenﬂuramine, 
previously available in the United States, have also been caus-
ally associated with an increased risk for PAH (Abenhaim 
et al 1996; Simonneau et al 1998).
Prior to the development of disease-speciﬁc targeted PAH 
therapies, the median survival for subjects diagnosed with 
IPAH was approximately 2.8 years (D’Alonzo et al 1991). 
However, 2.8 years likely underestimates current survival as 
the course of the disease has been favorably altered by thera-
peutic medical advances since that early report. Prognosis 
is also dependent on the underlying etiology of the disease. 
The prognosis for patients with PAH associated with con-
nective tissue disease appears to be worse than those with 
IPAH. Estimates for 2-year survival of scleroderma patients 
with associated PAH are 40% compared with 48% for 3-year 
survival for patients with IPAH (Stupi et al 1986; D’Alonzo 
et al 1991). Survival in patients with HIV-associated PAH 
is similar to patients with IPAH (Opravil et al 1997; 
McLaughlin et al 2004). With current HIV therapies, most 
of the deaths in patients with HIV and associated PAH are 
now attributed to PAH.
Although the exact cause(s) of PAH is unknown, current 
dogma suggests that PAH likely represents the ﬁnal outcome 
of multiple biologic abnormalities within the pulmonary 
circulation. Of signiﬁcance to this review, many studies 
Table 1 Clinical classiﬁcation of pulmonary hypertension (Venice 
2003). Reprinted from Simonneau G, Galie N, Rubin LJ, et al. 2004. 
Clinical classiﬁcation of pulmonary hypertension. J Am Coll Cardiol, 
43:5S–12S. Copyright © 2004 with permission from American 
College of Cardiology Foundation
1. Pulmonary arterial hypertension (PAH)
  1.1 Idiopathic (IPAH)
  1.2 Familial (FPAH)
  1.3 Associated with (APAH):
    1.3.1 Collagen vascular disease
    1.3.2 Congenital systemic-to-pulmonary shunts
    1.3.3 Portal hypertension 
    1.3.4 HIV infection
    1.3.5 Drugs and toxins
    1.3.6 Other (thyroid disorders, glycogen storage disease,  
    Gaucher disease, hereditary hemorrhagic telangiectasia,  
    hemoglobinopathies, myeloproliferative disorders, splenectomy)
  1.4 Associated with signiﬁcant venous or capillary involvement
    1.4.1 Pulmonary veno-occlusive disease (PVOD)
    1.4.2 Pulmonary capillary hemangiomatosis (PCH)
  1.5 Persistent pulmonary hypertension of the newborn
2. Pulmonary hypertension with left heart disease
  2.1 Left-sided atrial or ventricular heart disease
  2.2 Left-sided valvular heart disease
3. Pulmonary hypertension associated with lung diseases and/or 
hypoxemia
  3.1 Chronic obstructive pulmonary disease
  3.2 Interstitial lung disease
  3.3 Sleep-disordered breathing
  3.4 Alveolar hypoventilation disorders
  3.5 Chronic exposure to high altitude
  3.6 Developmental abnormalities
4. Pulmonary hypertension due to chronic thrombotic and/or 
embolic disease
  4.1 Thromboembolic obstruction of proximal pulmonary arteries
  4.2 Thromboembolic obstruction of distal pulmonary arteries
  4.3 Non-thromboembolic pulmonary embolism (tumor, parasites, 
foreign material)
5. Miscellaneous
  Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of 
pulmonary vessels (adenopathy, tumor, ﬁbrosing mediastinitis)
Abbreviations: HIV, human immunodeﬁciency virus.Vascular Health and Risk Management 2007:3(1)  13
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implicate pulmonary endothelial cell dysfunction in PAH 
pathobiology. Vasoactive agents produced from endothelial 
cells modulate pulmonary vascular smooth muscle cell tone 
in healthy subjects and maintain the normal pulmonary vascu-
lar smooth muscle in a state of relaxation (Vane et al 1990). The 
increased pulmonary vascular reactivity and vasoconstriction 
that characterize patients with PAH may be a result of loss of 
endothelial cell integrity (Higenbottam et al 1998). Indeed, 
dysfunctional endothelial cells are associated with increased 
production of vasoconstrictor mediators such as thromboxane 
A2, decreased synthesis of prostacyclin and nitric oxide, and 
uncontrolled proliferation (Rich 2001). In some patients with 
PAH, intimal proliferation progresses to almost complete 
occlusion of pulmonary arterioles (Edwards et al 1977; 
Pietra et al 1989). In addition, vasoactive mediators pro-
duced by endothelial cells may contribute to vascular 
remodeling (Botney 1999). Progression of PAH is accom-
panied by impaired endothelial cell functioning that is char-
acterized by an increase in vasoconstrictor and proliferative 
mediators and a decrease in vasodilator and antiproliferative 
mediators (Rich 2001). Drugs or drug classes that restore 
balance to modulation of pulmonary microvasculature tone 
could be expected to provide therapeutic beneﬁts.
Current treatment options for PAH
Only since 1996, with the introduction of intravenous epopros-
tenol, have disease-speciﬁc targeted medical therapies for PAH 
become available (Humbert et al 2004). Current treatments 
primarily target 3 established pathways in PAH pathobiology: 
the prostacyclin pathway, the nitric oxide pathway, and the 
endothelin-1 pathway (Fig. 1) (Humbert et al 2004).
Prostacyclin pathway
Prostacyclin and thromboxane A2 are metabolites of arachidonic 
acid that are produced by the vascular endothelium. Prostacy-
clin is a potent vasodilator in both the pulmonary and systemic 
circulations and has antiproliferative properties (Badesch 
et al 2004b; Rubin et al 2005a). Thromboxane A2 works in 
opposition to prostacyclin, inducing vasoconstriction and plate-
let aggregation (Gerber et al 1980; Farber et al 2004). In PAH, 
the balance between these two vasoactive mediators is shifted 
towards thromboxane A2, with decreases in the production of 
prostacyclin synthase leading to prostacyclin deﬁciency and 
thromboxane A2 excess (Christman et al 1992; Tuder et al 1999; 
Badesch et al 2004b). Exogenously administered prostacyclin 
or prostanoid analogues may help overcome the adverse effects 
of prostacyclin depletion (Badesch et al 2004b).
Continuous intravenous (IV) prostacyclin, that is, 
epoprostenol, has been shown in prospective randomized 
controlled trials to improve exercise capacity, quality of life 
(as measured by the Chronic Heart Failure Questionnaire, 
the Nottingham Health Proﬁle, and the Dyspnea-Fatigue 
Rating), symptoms, and cardiopulmonary hemodynamics 
in PAH (Barst et al 1994, 1996, 1999; Shapiro et al 1997; 
McLaughlin et al 1998). In addition, epoprostenol is the 
only available therapy shown to improve survival in IPAH 
in a placebo-controlled clinical trial (Barst et al 1994, 1996). 
The beneﬁcial effects of prostacyclin therapy are likely due 
to its vasodilating effects on pulmonary arterioles, inhibition 
of platelet aggregation, and inhibition of smooth muscle 
cell proliferation. In addition, epoprostenol appears to have 
positive inotropic properties and may have anti-inﬂammatory 
actions (Baumhakel et al 2005). Two other prostacyclin 
analogues, subcutaneous or IV treprostinil, and inhaled 
iloprost, are also approved in the United States. Currently, 
prostacyclin treatments are most often reserved for more 
severe cases based on overall risk-beneﬁt considerations. 
Members of this drug class are limited by short half-life, 
which requires continuous IV administration (epoprostenol 
or treprostinil), subcutaneous administration (treprostinil), 
or frequent inhalation therapy (iloprost) (Rubin et al 2005a). 
Additional limitations of these treatments include risk of in-
fections with IV epoprostenol or IV treprostinil from central 
venous catheters, and site pain with subcutaneous treprostinil, 
not infrequently leading to treatment discontinuation with 
subcutaneous treprostinil. Epoprostenol therapy remains the 
treatment of choice for severely ill patients. 
Nitric oxide pathway
Nitric oxide (NO) is a potent pulmonary vasodilator and 
inhibitor of platelet activation and vascular smooth muscle 
cell proliferation. Synthesis of NO is catalyzed by the family 
of NO synthase enzymes; decreased levels of the endothelial 
isoform of NO synthase have been reported in pulmonary 
vascular tissue in patients with PAH (Giaid et al 1995). 
The effects of NO are mediated via cyclic guanosine 
monophosphate (cGMP) in vascular smooth muscle cells. 
The intracellular concentration of cGMP is regulated by 
phosphodiesterases, which rapidly degrade cGMP in vivo 
(Beavo et al 1990; Ahn et al 1991). Phosphodiesterase-5 
(PDE-5) is highly expressed in the lung, and its expression 
is increased in PAH (Braner et al 1993). Therefore, drugs 
that selectively inhibit PDE-5 may prolong endogenous NO 
signaling and prove efﬁcacious in PAH. Sildenaﬁl is a PDE-5 Vascular Health and Risk Management 2007:3(1)  14
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inhibitor that was originally approved for erectile dysfunction 
and was recently approved for the treatment of PAH (Weimann 
et al 2000; Rubin et al 2005a). In the SUPER-1 trial, three times 
daily sildenaﬁl improved exercise capacity (assessed by the 
6-minute walk test), WHO functional class, and decreased 
pulmonary arterial pressure and pulmonary vascular resistance 
(Galie et al 2005b). Tadalaﬁl, another PDE-5 inhibitor, is cur-
rently being evaluated for the treatment of PAH.
Endothelin pathway
Endothelin-1 (ET-1) is an endogenous peptide produced 
by vascular endothelial cells; it is one of the most potent 
vasoconstrictors and smooth-muscle cell mitogens (Hassoun 
et al 1992; Stelzner et al 1992). Endothelin-1 expression 
is elevated in plasma (Rubens et al 2001) and lung tissue 
(Giaid et al 1993) of patients with PAH. The magnitude of 
overexpression in ET-1 has been shown to correlate with 
disease severity (Galie et al 2004) and cardiopulmonary 
hemodynamics (Cacoub et al 1993; Nootens et al 1995; Cacoub 
et al 1997). Furthermore, the expression of ET-1 was inversely 
proportional to survival in a study of PAH patients treated 
with conventional therapy (Galie et al 2004).
Endothelin-1 exerts its effects through 2 endothelin recep-
tor isoforms: endothelin type-A (ETA) and type-B (ETB). The 
ETA receptors are primarily expressed on vascular smooth 
muscle cells and cardiac myocytes; in contrast, ETB receptors 
are localized predominantly on endothelial cells, and to a 
lesser extent, on smooth muscle cells and on ﬁbroblasts (Fig. 
2) (Dupuis 2001). Activation of the ETA isoform (and the ETB 
isoform on smooth muscle cells) induces vasoconstriction 
Figure 1 Postulated pathways in the pathobiology of pulmonary arterial hypertension (PAH) and drug classes targeting these pathways. Reprinted from Humbert M, Sitbon 
O, Simonneau G. 2004. Treatment of pulmonary arterial hypertension. N Engl J Med, 351:1425-36. Copyright © 2004 with permission from Massachusetts Medical Society. Vascular Health and Risk Management 2007:3(1)  15
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and proliferation of vascular smooth muscle cells through 
the activation of phospholipase C and subsequent increase 
of inositol triphosphate, diacylglycerol, and intracellular 
calcium (Pollock et al 1995). The mitogenic activity of ET-1 
is mediated by the activation of protein kinase C secondary to 
increases in diacylglycerol and calcium (Ohlstein et al 1992). 
The ETB receptors are principally involved in the clearance 
of ET-1, particularly in the vascular beds of the lungs and 
kidney, and may induces vasodilation via release of NO and 
prostacyclin from the endothelial cells (Hirata et al 1993; 
Rubin et al 2005a).
Endothelin receptor antagonism is a well-established 
approach to blocking the ET-1 system in PAH (Galie et al 
2004). Endothelin receptor antagonists (ERAs) are either 
ETA selective, such as sitaxsentan and ambrisentan, or non-
selective for the ETA and ETB receptors, such as bosentan. 
Selective inhibition of ETA receptors may be preferential 
to non-selective receptor antagonism by permitting main-
tenance of vasodilator and clearance functions speciﬁc to 
ETB receptors on the endothelial cells, while preventing 
the vasoconstriction and cellular proliferation mediated by 
ETA. Bosentan, an ETA/ETB non-selective, sulfonamide-
class ERA, was the ﬁrst approved ERA for the treatment of 
PAH. More recently, the ETA-selective, sulfonamide-class 
ERA sitaxsentan was  approved in the EU. Ambrisentan, a 
non-sulfonamide, propanoic-acid class, ETA-selective ERA, 




3-methoxy-3,3-diphenylpropanoic acid, is an ETA-selective 
ERA. In vitro studies with ambrisentan have demonstrated 
that it is a potent and selective inhibitor of the ETA recep-
tor. Studies using human ventricular myocyte-derived ETA 
and ETB receptors have shown that ambrisentan has a high 
binding afﬁnity for the ETA receptor, with a Ki (dissociation 
constant for the inhibitor) of approximately 0.011 nM and 
a selectivity for the ETA receptor over the ETB receptor of 
>4000:1, with no relevant binding to other receptors (Greene 
et al 2006). At therapeutically relevant plasma concentra-
tions, ambrisentan has high receptor occupancy with ETA 
(>90%), and low afﬁnity for ETB (<10%). Ambrisentan 
is a unique ERA. It differs from bosentan and sitaxsentan 
in that it is a propanoic acid-class molecule rather than 
a sulfonamide-class agent. The chemical composition of 
ambrisentan, also known as LU 208075 or BSF 208075, is 
C22H22N2O4, and its molecular weight is 378.4 g/mol (Rubin 
Figure 2 Schematic representation of the endothelin system in vascular tissue. Interactions of endothelin-1 with ETA on endothelial cells and ETA and ETB receptors on 
smooth muscle cells are shown. Reprinted from Dupuis J. 2001. Endothelin-receptor antagonists in pulmonary hypertension. Lancet, 358:1113-4. Copyright © 2001 with 
permission from Elsevier. 
Abbreviations: ET-1, endothelin-1; BIG-ET-1, proendothelin-1; ECE, endothelin-converting enzyme; NO, nitric oxide; PGI2, prostacyclin. Vascular Health and Risk Management 2007:3(1)  16
Barst
et al 2005b). The structural formula of ambrisentan is shown 
in Figure 3.
Pharmacokinetics
Ambrisentan is rapidly absorbed into the systemic circulation 
following oral administration, with high oral bioavailability 
(Rubin et al 2005b). The pharmacokinetics of ambrisentan 
are dose-linear over a range of 1–100 mg and are not affected 
by food intake. Steady-state is achieved after 3–4 days of 
once-daily oral dosing with ambrisentan, and the pharmaco-
kinetics of multiple doses (ie, steady-state ambrisentan) are 
consistent with observations after a single dose (Rubin et al 
2005b). The steady-state elimination half-life of ambrisentan 
in PAH patients is approximately 15 hours for the 5 mg dose, 
providing the rationale for once-daily dosing (Oudiz 2006; 
Rubin et al 2005b).
The main metabolic pathways of ambrisentan appears to 
be hepatic phase II glucuronidation of the parent compound, 
and to a lesser extent phase I hydroxylation. Moreover, in 
vitro and in vivo animal model studies with ambrisentan 
concentrations that exceeded therapeutic levels demonstrated 
that ambrisentan had little effect on hepatic enzyme (eg, 
CYP2C9, CYP3A4, or CYP1A2) induction or inhibition. 
Following oral administration of a radiolabeled dose in 
preclinical studies, ambrisentan was primarily detected in 
the liver and plasma 2–4 hours after administration. The 
majority of the radiolabeled dose was recovered in the feces 
as unchanged or glucuronide-conjugated drug.
Drug–drug interactions
Current sulfonamide-class ERAs developed for the treat-
ment of PAH are associated with potentially signiﬁcant 
drug-drug interactions. Bosentan induces the cytochrome 
P450 isoenzymes CYP2C9 and CYP3A4 and may decrease 
the systemic exposure of other drugs that share this meta-
bolic pathway (Kenyon et al 2003). Similarly, sitaxsentan 
inhibits the activity of CYP2C9, thereby increasing sys-
temic exposure to drugs metabolized by this cytochrome 
P450 isozyme (Barst et al 2004a). Both bosentan and sitax-
sentan alter the pharmacokinetics of warfarin (Kenyon et al 
2003; Badesch et al 2004a; Dingemanse et al 2004; Barst 
et al 2006). While the effects of concomitant bosentan may 
or may not require adjustment of warfarin dose, an 80% 
reduction in the dose of warfarin was used in the clinical 
studies of sitaxsentan to prevent over-anticoagulation and 
the potential for bleeding (Barst et al 2006). Additional 
drugs commonly prescribed to patients with PAH that 
are metabolized by the cytochrome P450 system include 
sildenaﬁl, hormonal contraceptives, glyburide, cyclosporin 
A, and statins.
Potential drug–drug interactions between ambrisentan 
and sildenaﬁl, and between ambrisentan and warfarin were 
evaluated in healthy subjects co-administered ambrisentan 
plus sildenaﬁl or ambrisentan plus warfarin, respectively. 
Pharmacokinetic parameters of ambrisentan and sildenaﬁl 
were similar when administered as monotherapy or in 
combination (Dufton et al 2006). The pharmacokinetics of 
n-desmethyl-sildenaﬁl, the active metabolite of sildenaﬁl, 
were also unaffected by multiple doses of ambrisentan 
(Dufton et al 2006). Similarly, the pharmacokinetics of 
warfarin enantiomers and ambrisentan were not appreciably 
inﬂuenced by concomitant administration (Gerber et al 2006). 
Moreover, co-administration of multiple ambrisentan doses 
had no clinically relevant effect on the prothrombin time 
or international normalized ratio following a single dose of 
warfarin (Gerber et al 2006). In both studies, ambrisentan 
was well tolerated and no safety concerns arose with the 
combination therapies.
The lack of pharmacodynamic effect of ambrisentan on 
warfarin has been conﬁrmed in ambrisentan clinical trials 
to date, which allowed the use of warfarin or warfarin-like 
anticoagulants as concomitant medications. In a Phase 2, 
dose-ranging study, prothrombin time, international nor-
malized ratio, and anticoagulant dose were unaffected by 
ambrisentan treatment (Galie et al 2005a). Similar results 
were reported for warfarin-type anticoagulant dosing in 
the Phase 3 ambrisentan trials (Olschewski et al 2006; 
Oudiz 2006). These data suggest that dosage adjustment 
of warfarin is not needed during concomitant ambrisentan 
therapy.  Figure 3 The chemical structure of ambrisentan.Vascular Health and Risk Management 2007:3(1)  17
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Clinical efﬁcacy
To date, a total of 7 Phase 2 or 3 trials of ambrisentan have 
been completed or are ongoing. In the Phase 2, double-blind, 
dose-ranging study, 64 patients with IPAH or PAH associated 
with connective tissue disease, anorexigen use, or HIV were 
randomized to receive oral ambrisentan 1, 2.5, 5, or 10 mg 
once-daily for 12 weeks, followed by a 12-week open-label 
treatment period (Galie et al 2005a). The primary endpoint 
was the change from baseline in 6-minute walk distance 
(6MWD). Secondary endpoints included change from base-
line in WHO functional class, Borg dyspnea index (BDI), 
subject global assessment, and cardiopulmonary hemody-
namics. By week 12, 6MWD had signiﬁcantly improved for 
all dose groups (p < 0.02), with a mean increase of +36 m for 
the combined analysis (p < 0.001) (Fig. 4a) and the magnitude 
of increase in 6MWD was comparable regardless of baseline 
WHO functional class. Exercise capacity continued to increase 
throughout the study, reaching a maximum improvement from 
baseline of +54 m at week 24 (Fig. 4b). 
Measurable improvements with ambrisentan treatment 
were also observed in WHO functional class (Fig. 5), BDI, 
subject global assessment, and cardiopulmonary hemody-
namics (Galie et al 2005a). Eighteen (36%) patients expe-
rienced clinical improvements of sufﬁcient magnitude to 
improve WHO functional class by 1 or more classes, whereas 
only 2 (3.4%) patients deteriorated in WHO functional class. 
Decreases (ie, improvement) in BDI ranged from –0.6 ± 0.5 
in the 1 mg dose group to –1.0 ± 0.6 in the 5 and 10 mg 
dose groups at week 12, and the average reduction in BDI 
across dose groups was –1.3 ± 0.3 at week 24 (p < 0.0001). 
Signiﬁcant improvements were also observed in quality of 
life, as measured by a subject global assessment (11.3 ± 2.4 
and 12.1 ± 2.7 mm at weeks 12 and 24, respectively; 
p < 0.0001). In the combined analysis of all dose groups, 
cardiac index increased, and mean pulmonary arterial pres-
sure and pulmonary vascular resistance decreased compared 
with baseline (p < 0.05). 
Patients who completed the 24-week study were eligible 
to participate in a long-term, open-label extension study. 
Fifty-four patients continued treatment and 50 of these pa-
tients were receiving ambrisentan monotherapy after 1 year 
(48 weeks) of treatment (Galie et al 2005c). A combined 
analysis of the overall patient population demonstrated that 
the clinical beneﬁts of ambrisentan were sustained over the 
1-year study period, including improvements in 6MWD 
(mean increase 55 ± 55 m, p < 0.0001 for all dose groups 
combined), BDI, and WHO functional class. 
Ambrisentan was also evaluated in two Phase 3 random-
ized, double-blind, placebo-controlled, multicenter studies 
(ARIES-1 and ARIES-2: Ambrisentan in PAH- A Phase III, 
Randomized, Double-blind, Placebo-controlled, Multicenter 
Efﬁcacy Study of Ambrisentan in Subjects with Pulmonary 
Arterial Hypertension) in patients with IPAH or PAH associ-
ated with connective tissue disease, anorexigen use, or HIV 
infection. Both Phase 3 studies have been completed, and a 
combined long-term extension study is ongoing.
The ARIES-1 study assessed the efﬁcacy and safety of 
once-daily ambrisentan 5 or 10 mg versus placebo. A total 
of 202 patients were randomized to 1 of these 3 treatment 
groups for the 12-week study duration. Signiﬁcant improve-
ments in the placebo-corrected 6MWD change from baseline 
Figure 4A Ambrisentan at all dose levels signiﬁcantly increased exercise capacity 
as assessed by the 6-minute walk test from baseline to week 12 in patients with 
pulmonary arterial hypertension. (4B) Improvements in 6-minute walk distance 
(6MWD) were maintained over 24 weeks; Data are mean ± standard error. 
*p < 0.02, †p < 0.001 versus baseline. Reprinted from Galie N, Badesch D, Oudiz R, 
et al. 2005a. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll 
Cardiol, 46:529–35. Copyright © 2005 with permission from American College of 
Cardiology Foundation.Vascular Health and Risk Management 2007:3(1)  18
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to week 12 versus placebo were seen with both dose groups 
(+31 m for 5 mg, p = 0.008; +51 m for 10 mg; p < 0.001). 
Improvements in WHO functional class and Borg dyspnea 
index were also observed (Oudiz et al 2006). Although 6 
patients in the placebo group developed clinical worsening, 
compared with 3 patients in each of the ambrisentan groups, 
this difference was not statistically signiﬁcant. Clinical 
worsening of PAH was predeﬁned as: death, lung transplan-
tation, hospitalization for PAH, atrial septostomy, or study 
withdrawal due to initiation of other PAH therapies or 2 or 
more early escape criteria.
In the ARIES-2 study, 192 patients with PAH were 
randomized to receive ambrisentan 2.5 or 5 mg or placebo 
once-daily for 12 weeks (Olschewski et al 2006). Ambris-
entan signiﬁcantly improved the placebo-corrected 6MWD 
at week 12 for patients treated with ambrisentan 2.5 mg 
(+32 m, p = 0.022) or 5 mg (+59 m, p < 0.001). In addition, 
ambrisentan delayed time to clinical worsening in each 
dose group versus placebo (2.5 mg: p = 0.005; 5 mg: p = 
0.008). Improvements in BDI and the SF-36® Health Survey 
were also reported to be better in the ambrisentan-treated 
patients compared with the placebo-treated patients. Six 
patients died: 4 patients in the placebo group, 2 patients 
treated with ambrisentan 2.5 mg, and no patients who received 
ambrisentan 5 mg. 
An integrated analysis of ARIES-1 and ARIES-2 conﬁrmed 
a signiﬁcant and dose-dependent increase in 6MWD with 
ambrisentan treatment. All secondary efﬁcacy endpoints demon-
strated signiﬁcant improvements for the combined ambrisentan 
group and in the individual 5 and 10 mg dose groups (p < 0.05). 
In addition, signiﬁcant improvements in time to clinical worsening 
were seen in the combined ambrisentan group (p = 0.0003) and 
in each of the individual dose groups (p <0.03). 
Safety
Ambrisentan was generally safe and well tolerated in all 
the PAH clinical studies. The most frequently reported 
adverse events during the Phase 2, dose-ranging study were 
peripheral edema, nasal congestion, upper respiratory tract 
infection, headache, ﬂushing, and nausea (Galie et al 2005a) 
and did not appear to be dose related. Ambrisentan was well 
tolerated throughout the 1-year extension study, with no 
emergent safety signals apparent during long-term therapy 
(Galie et al 2005c). 
Figure 5 Ambrisentan improved World Health Organization functional class in patients with pulmonary arterial hypertension. Black bars = Class I, grey bars = Class II, 
white bars = Class III. Reprinted from Galie N, Badesch D, Oudiz R, et al. 2005a. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol, 46:529–35. 
Copyright © 2005 with permission from American College of Cardiology Foundation.Vascular Health and Risk Management 2007:3(1)  19
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Hepatic safety
Liver abnormalities have been associated with the sulfon-
amide-class ERAs and to date necessitate monthly liver 
function testing (LFT). In the placebo-controlled PAH stud-
ies of bosentan (Bosentan Randomized Trial of Endothelin 
Antagonist Therapy, BREATHE-1 and Study 351), 12% and 
14% of patients, respectively, developed hepatic aminotrans-
ferase concentrations >3 × the upper limit of normal (ULN) 
and 3% and 7% of patients developed hepatic aminotrans-
ferase concentrations >8 × ULN respectively following the 
oral twice-daily administration of 125 and 250 mg bosentan. 
Three (2%) patients (all in the 250 mg group) withdrew from 
treatment because of LFT abnormalities (Rubin et al 2002; 
Channick et al 2001). In the 18-week Sitaxsentan To Relieve 
ImpaireD Exercise-2 (STRIDE-2) study, the incidence of 
hepatic aminotransferases > 3 × ULN was 5% for sitaxsentan 
50 mg, 3% for sitaxsentan 100 mg, and 11% for bosentan 
(Barst et al 2006).
In contrast to bosentan, ambrisentan has demonstrated a 
lower incidence of acute hepatotoxicity in the Phase 2 and 
3 clinical trials. During the Phase 2, 24-week study, 2 (3%) 
patients experienced elevations in hepatic aminotransferases 
>3 × ULN that required dose reduction or drug discontinua-
tion; an additional 2 patients had isolated elevations that were 
unconﬁrmed upon retest and required no change in treatment 
(Galie et al 2005a). At the start of the long-term extension 
study (ie. after 24 weeks of ambrisentan treatment), 48% of 
patients were receiving the maximal dose of ambrisentan (10 
mg); no additional elevations of ALT and/or AST >3 × ULN 
were observed after one year follow-up (Galie et al 2005c). In 
the pivotal 12-week ARIES-2 study, no patients treated with 
ambrisentan developed hepatic aminotransferases >3 × ULN, 
compared with 1 patient in the placebo group (Olschewski 
et al 2006). Similar results were reported for the pivotal 12-
week ARIES-1 study, that is, no patients treated with ambrisen-
tan developed hepatic aminotransferases >3 × ULN, compared 
with 2 patients in the placebo group (Oudiz et al 2006).
An open-label Phase 2 study of ambrisentan was performed 
to evaluate the risk of LFT abnormalities in patients with PAH 
who had previously discontinued bosentan and/or sitaxsentan 
because of liver toxicity. Thirty-six patients were evaluated, 
86% of whom had discontinued bosentan, 6% had discontin-
ued sitaxsentan, and 8% had discontinued both. The median 
duration of treatment with ERA prior to discontinuation 
was 9 weeks (McGoon et al 2006). None of the 36 patients 
enrolled in the study had a recurrence of LFT abnormalities 
that resulted in discontinuation of ambrisentan during the initial 
12-week evaluation period. One patient experienced a transient 
increase in hepatic aminotransferase >3 × ULN that resulted 
in dose reduction. No further elevations >3 × ULN have been 
observed with ambrisentan exposure of more than 1 year.
Decreases in hemoglobin concentration have also been 
recognized as a class effect associated with ERAs (Galie 
et al 2005a). In the Phase 2 ambrisentan trial, decreases in 
hemoglobin concentrations were observed as early as week 
2 and remained stable throughout the 12 week study (mean 
change from baseline to week 12 was –0.8 g/dL); however 
no further decreases were observed during the subsequent 
12-week, open-label treatment period. Furthermore, although 
both sitaxsentan and bosentan alter the pharmacokinetics of 
warfarin (Kenyon et al 2003; Badesch et al 2004a; Dingemanse 
et al 2004; Barst et al 2006), no clinically relevant changes 
in warfarin-like anticoagulant therapy have been observed 
in any of the Phase 2 or 3 ambrisentan clinical trials to date 
(Galie et al 2005a, 2005c; McGoon et al 2006; Olschewski 
et al 2006; Oudiz et al 2006).
Conclusions
Ambrisentan is a selective ETA receptor antagonist that 
appears to provide signiﬁcant clinical beneﬁt in the treat-
ment of patients with PAH. In Phase 2 and 3 clinical trials, 
ambrisentan improved exercise capacity, dyspnea, time to 
clinical worsening, WHO functional class, quality of life, and 
cardiopulmonary hemodynamic parameters. Ambrisentan 
appears to be safe and well tolerated, with a low incidence 
of acute hepatotoxicity. Ambrisentan has an improved safety 
proﬁle compared with sulfonamide-class ERAs with respect 
to the potential for hepatic toxicity and the potential for drug-
drug interactions with agents metabolized by P450 enzymes 
such as warfarin and sildenaﬁl. These data support the role 
of ambrisentan for the treatment of PAH. 
Expert opinion
Given the signiﬁcant role that ET-1 seems to play in the 
pathobiology of PAH, there is a strong rationale for the use 
of ERAs in the treatment of PAH. A selective ETA receptor 
antagonist may afford us the opportunity of blocking the 
actions of ET-1 at the predominant vasoconstrictor recep-
tor subtype, that is, ETA receptor, while permitting ongoing 
stimulation of the vasodilatory ETB receptor on endothelial 
cells, in addition to preserving ET-1 pulmonary clearance. 
However, as the functions of both the ETA and ETB receptors 
may differ in various disease states as compared with the 
normal pulmonary vasculature, it remains unclear whether Vascular Health and Risk Management 2007:3(1)  20
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a selective ETA receptor antagonist or an ETA/ETB receptor 
antagonist will prove to be more efﬁcacious in the treatment 
of PAH. In addition, whether various PAH subgroups such 
as PAH associated with connective tissue disease or associ-
ated with congenital heart disease may respond more or less 
favorably with a selective ETA receptor antagonist than with 
an ETA/ETB receptor antagonist is also currently unknown.
The ETA-selective ERA ambrisentan holds promise in 
advancing both the safety and convenience of oral PAH 
treatment. Ambrisentan, a once-daily oral treatment, does 
not induce or inhibit cytochrome P450 enzymes; therefore, 
ambrisentan may be preferable to other currently avail-
able ERAs when used in conjunction with other medica-
tions prescribed for patients with PAH. In clinical trials 
with ambrisentan, there appears to be a low risk for acute 
hepatotoxicity. Current evidence suggests that the hepatic 
aminotransferase increases seen with bosentan may result 
from intermittent uncoupling of lipid and bile salt excretion 
that results in intracellular accumulation of bile salts (Fat-
tinger et al 2001; Fouassier et al 2002). Therefore, an ERA 
metabolized by a different pathway that does not inhibit 
bile salt secretion may be less likely to lead to acute hepa-
totoxicity. This is an intriguing hypothesis that is currently 
under investigation. 
It has been an exciting time for the treatment of patients 
with PAH, with new drugs becoming available, such as pros-
tacyclin analogues, ERAs, and PDE-5 inhibitors. Whether 
there is an additive or synergistic effect of an ERA with a 
prostanoid (eg, epoprostenol, iloprost, or treprostinil) and/or a 
PDE-5 inhibitor (eg, sildenaﬁl or tadalaﬁl) is yet to be deter-
mined. As observed in many chronic diseases, for example, 
diabetes, congestive heart failure and asthma, combination 
therapy may improve the overall efﬁcacy for treating patients 
with PAH. An oral once-daily agent with a low risk for liver 
function abnormalities and drug–drug interactions could con-
fer advantages to the agent’s use in combination regimens, a 
current area of active investigation and optimism.
The treatment algorithm continues to evolve as newer 
agents become available. Future developments in vascular 
biology will improve our understanding of the pathobiology 
of PAH, as well as provide rationale for more disease-speciﬁc 
targeted therapies. Preclinical and clinical investigations are 
currently being explored with PDGF inhibitors, vasoactive 
intestinal peptide, selective 5HT2B antagonists, statins, 
kinase inhibitors and/or gene therapy. With the advent of 
genomic technologies and methods, the necessary tools are 
now becoming available to begin pinpointing the genes that 
contribute to disease susceptibility and progression. Candi-
date gene discovery, that is, gene analysis using microarrays, 
can identify genes that may provide valuable insight into 
disease biology and may represent an initial step towards 
the identiﬁcation of genetic polymorphisms that may help 
predict efﬁcacy, or lack thereof, with various disease-speciﬁc 
targeted PAH therapeutic modalities. By identifying the 
genes and gene variants that determine individual disease 
susceptibility, we might be able to identify patients in pre-
clinical stages of disease as well as allow for individualized 
therapies that are most efﬁcacious and least likely to cause 
side effects. Ultimately, as these novel therapeutic options 
are developed, individualized treatment regimens will evolve. 
We hope that by further increasing our understanding of the 
pathobiology of PAH, we will one day be able to prevent 
and cure this disease. 
Further development of ambrisentan for the treatment of 
PAH is anticipated, as are long-term survival data from the 
ARIES-1 and ARIES-2 trials.
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